Roche Holding AG RHHVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RHHVF is a good fit for your portfolio.
News
-
Roche Breast-Cancer Drug Gets Priority Review in the U.S.
-
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog
-
Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation
-
U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx
-
Roche ramps up obesity-drug competition with early-stage trial results
-
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial — Update
-
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial
-
Roche prepares for business after boom from COVID-related products
Trading Information
- Previous Close Price
- $270.09
- Day Range
- $269.69–269.69
- 52-Week Range
- $233.12–319.47
- Bid/Ask
- $270.12 / $275.70
- Market Cap
- $215.01 Bil
- Volume/Avg
- 10 / 10,150
Key Statistics
- Price/Earnings (Normalized)
- 12.40
- Price/Sales
- 3.23
- Dividend Yield (Trailing)
- 4.02%
- Dividend Yield (Forward)
- 4.02%
- Total Yield
- 4.02%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 103,605
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RHHVF
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.40 | 59.67 | 15.38 |
Price/Book Value | 6.17 | 8.12 | 37.18 |
Price/Sales | 3.23 | 5.37 | 5.49 |
Price/Cash Flow | 11.88 | 18.88 | 15.89 |
Price/Earnings
RHHVF
MRK
ABBV
Financial Strength
|
Metric
|
RHHVF
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.99 | 0.68 | 0.72 |
Current Ratio | 1.35 | 1.25 | 0.94 |
Interest Coverage | 14.93 | 3.97 | 3.95 |
Quick Ratio
RHHVF
MRK
ABBV
Profitability
|
Metric
|
RHHVF
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 17.03% | 5.22% | 14.14% |
Return on Equity (Normalized) | 53.42% | 13.56% | 172.29% |
Return on Invested Capital (Normalized) | 26.30% | 8.29% | 27.87% |
Return on Assets
RHHVF
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Hwhsnync | Rmv | $834.9 Bil | |||
| Johnson & Johnson
JNJ
| Mfmsxlvsg | Yxpks | $350.3 Bil | |||
| Merck & Co Inc
MRK
| Pggxnymzt | Sjrbt | $327.9 Bil | |||
| AbbVie Inc
ABBV
| Rzxpgtg | Mnwgd | $297.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Cyxbblqsh | Fzjb | $247.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Tfypmmbfsn | Xjpgv | $223.9 Bil | |||
| Novartis AG ADR
NVS
| Qqzqbnq | Hxwpf | $216.8 Bil | |||
| Amgen Inc
AMGN
| Ffvkcxcs | Lsvj | $160.2 Bil | |||
| Pfizer Inc
PFE
| Tydllrdn | Cgsz | $156.0 Bil | |||
| Sanofi SA ADR
SNY
| Tnsxlglm | Wryt | $116.1 Bil |